Cytidine-5'-triphosphate (disodium)

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: Cytidine-5'-triphosphate (disodium)
• 英文别名: disodium;[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
• 化学式: C9H14N3Na2O14P3
• 分子量: 527.12
• InChiKey: NFQMDTRPCFJJND-WFIJOQBCSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -10.51
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  280
• 氢给体数：
  5
• 氢受体数：
  14

文献信息

• [EN] N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO<br/>[FR] N4-HYDROXYCYTIDINE, SES DÉRIVÉS ET UTILISATIONS ANTI-VIRALES
  申请人：UNIV EMORY

  公开号：WO2016106050A1

  公开（公告）日：2016-06-30

  This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.

  这项披露涉及N4-羟基胞嘧啶衍生物、组合物以及相关方法。在某些实施方式中，该披露涉及治疗和预防病毒感染。
• [EN] N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO<br/>[FR] N4-HYDROXYCYTIDINE ET DÉRIVÉS ET LEURS UTILISATIONS ANTI-VIRALES
  申请人：UNIV EMORY

  公开号：WO2017156380A1

  公开（公告）日：2017-09-14

  This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.

  这项披露涉及某些N4-羟基胞嘧啶衍生物，相关组合物和方法。在某些实施例中，该披露涉及治疗或预防寨卡病毒感染。
• [EN] N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO<br/>[FR] N4-HYDROXYCYTIDINE ET SES DÉRIVÉS ET UTILISATIONS ANTIVIRALES ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2021159044A1

  公开（公告）日：2021-08-12

  This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

  这项披露涉及某些N4-羟基胞苷衍生物、药物组合物以及相关方法。在某些实施方式中，该披露涉及治疗或预防人类冠状病毒2019-nCoV。
• Method of producing 6-thio-sialylated glycoproteins and glycoconjugates
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：EP1911850A1

  公开（公告）日：2008-04-16

  The present invention relates to a method of preparing 6-thio-sialyl-glycosyl compounds, comprising the step consisting of reacting in vitro or in vivo 6-thio-sialic acid compounds with a CMP-sialic synthetase to form CMP-6-thio sialic acid compounds and with a sialyltransferase to transfer said CMP-6-thio sialic acid compounds as donor substrate to glycosyl compounds as acceptor subtrate leading to the enzymatic coupling of 6-thiosialic acid compounds onto glycosyl compounds. Glycosyl compounds are selected from glycoproteins, glycolipids and oligosaccharides, including monoclonal antibodies.

  本发明涉及一种制备6-硫代硅烷基-糖基化合物的方法，包括以下步骤：在体外或体内将6-硫代硅烷基化合物与CMP-硅烷基合成酶反应，形成CMP-6-硫代硅烷基化合物，并与硅烷基转移酶反应，将所述CMP-6-硫代硅烷基化合物作为供体底物转移到作为受体底物的糖基化合物上，导致6-硫代硅烷基化合物与糖基化合物的酶偶联。糖基化合物可选自糖蛋白、糖脂和寡糖，包括单克隆抗体。
• PHARMACEUTICAL COMPOSITIONS COMPRISING N4-HYDROXYCYTIDINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF INFLUENZA OR CORONAVIRUS INFECTIONS
  申请人：Emory University

  公开号：EP3939985A1

  公开（公告）日：2022-01-19

  The present invention relates to pharmaceutical compositions comprising N4-hydroxycytidine derivatives of formula I for use in the treatment or prevention of infections caused by influenza virus including influenza A virus, subtype H1N1, H3N2, H7N9, or H5N1, influenza B virus, and influenza C virus, human coronavirus, and SARS coronavirus.

  本发明涉及由式 I 的 N4-羟基胞嘧啶衍生物组成的药物组合物 用于治疗或预防由流感病毒（包括甲型流感病毒、H1N1、H3N2、H7N9 或 H5N1 亚型、乙型流感病毒、丙型流感病毒、人类冠状病毒和 SARS 冠状病毒）引起的感染。